Suchergebnisse - "O'Day, Steven J"

PubPharm (16)

1

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma : Pooled Analysis of 3 Clinical Trials

enthalten in: JAMA oncology | 2020

von Puzanov, I. | Ribas, A. | Robert, C. | +18

2

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2015

von Ribas, A. | Puzanov, I. | Dummer, R. | +33

CommentIn: Lancet Oncol. 2015 Aug;16(8):873-4. - PMID 26115798

3

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2013

von Hodi, F. | Corless, C. | Giobbie-Hurder, A. | +21

CommentIn: J Clin Oncol. 2013 Sep 10;31(26):3173-5. - PMID 23940226

4

Final results of phase III SYMMETRY study : randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2013

von O'Day, S. | Eggermont, A. | Chiarion-Sileni, V. | +16

5

Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma

enthalten in: Investigational new drugs | 2012

von O'Day, S. | Pavlick, A. | Albertini, M. | +7

6

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours : a phase 1 dose-escalation trial

enthalten in: Lancet (London, England) | 2012

von Falchook, G. | Long, G. | Kurzrock, R. | +14

CommentIn: Lancet. 2012 May 19;379(9829):1858-9. - PMID 22608322

7

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

enthalten in: The New England journal of medicine | 2011

von Chapman, P. | Hauschild, A. | Robert, C. | +126

CommentIn: N Engl J Med. 2011 Jun 30;364(26):2547-8. - PMID 21639809

8

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

enthalten in: Investigational new drugs | 2011

von Hersh, E. | O'Day, S. | Powderly, J. | +7

9

Improved survival with ipilimumab in patients with metastatic melanoma

enthalten in: The New England journal of medicine | 2010

von Hodi, F. | O'Day, S. | McDermott, D. | +26

ErratumIn: N Engl J Med. 2010 Sep 23;363(13):1290

10

Ipilimumab monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging study

enthalten in: The Lancet. Oncology | 2010

von Wolchok, J. | Neyns, B. | Linette, G. | +14

CommentIn: Lancet Oncol. 2010 Feb;11(2):108-9. - PMID 20152761